News

David McWilliams, the former CEO, will continue to serve on the board of directors and in a consulting capacity during the transition. Mr McWilliams has served as president,

The company has requested priority review of its US application and, if granted, Mozobil could be approved by the end of 2008. European approval is expected in 2009.

Under terms of the agreement, MonoSol Rx will receive milestone payments prior to commercial launch and sales-based milestones that could total $23.5 million as well as payments for

The Phase I trial is expected to enroll up to 63 patients with advanced metastatic cancer who have failed or are intolerant of standard therapy. Patients will receive

The patent was issued to Eurand, the developer of Amrix, and expires on February 26, 2025. In 2007, Cephalon acquired an exclusive license from Eurand to market Amrix

The company is analyzing the applicable tax, if any, on the payment of $2.33 million to the company, and will revise its 2008 fiscal year earnings per share

Prior to joining Zelos Therapeutics, Mr Roemer worked at Pharmasset from 1999 through 2008. Before joining Pharmasset, Mr Roemer was a healthcare consultant for Booz-Allen & Hamilton and

The Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study will involve up to 53 subjects with secondary progressive multiple sclerosis who will receive the drug once weekly in

The Phase I/II clinical trial is primarily designed to assess the safety, tolerability, and pharmacokinetics of the drug. As a secondary objective, anticancer effects will be documented whenever